Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 10584 participants.

Also called NCT03315143

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 10,584 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03315143
Other papers using this trial's data
  • Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial The lancet. Diabetes & endocrinology, 2025-04 DOI, PubMed 39961315
  • Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial Clinical journal of the American Society of Nephrology : CJASN, 2024-05-01 DOI, PubMed 38277468, PMC11108248 In the PMC Open Access subset under CC BY.
  • Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease The New England journal of medicine, 2021-01-14 DOI, PubMed 33200891

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Estonia, France, Georgia, Germany, Greece, Guatemala, Hungary, India, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, North Macedonia, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03315143. Randomized; quadruple masking; primary purpose prevention. Start 2017-12-19 (actual); primary completion 2020-07-08 (actual). Results posted on 2022-10-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
Acronym
SCORED
Condition
Heart Failure
Condition
Type 2 Diabetes Mellitus
Condition
Chronic Kidney Diseases
Intervention (Drug)
Sotagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03315143
Content hash
7761ea7e8a701129f22c282e3b46dbb62ee80f31c7aa9fd05f342d5a00478c88